<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558270</url>
  </required_header>
  <id_info>
    <org_study_id>GOETHE_V2</org_study_id>
    <nct_id>NCT02558270</nct_id>
  </id_info>
  <brief_title>Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism</brief_title>
  <official_title>Acute Effects of Sodium GlucOse Co-Transporter 2 (SGLT2) Inhibition on Hepatic Glucose and Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhibition of SGLT2 by specific inhibitors has been shown to reduce the renal threshold for&#xD;
      glucose excretion in patients with type 2 diabetes mellitus (T2DM) and control subjects&#xD;
      leading to significant renal glucose loss even in the presence of normal glucose&#xD;
      concentrations. SGLT2 inhibition with canagliflozin induces a 24h urinary glucose loss of&#xD;
      around 70g in healthy subjects.&#xD;
&#xD;
      Recent studies indicate that under fasting and postprandial conditions administration of&#xD;
      SGLT-2 inhibitors leads to increase in endogenous (hepatic) glucose production (EGP)&#xD;
      potentially counteracting the glucose lowering potency of these drugs. Dapagliflozin has been&#xD;
      shown to acutely increase endogenous glucose production (EGP) and plasma glucagon&#xD;
      concentrations under postabsorptive conditions within 2 hours after drug ingestion in&#xD;
      patients with (T2DM). Glucagon binds to receptors in the liver and activates hepatic&#xD;
      gluconeogenesis (GNG) and glycogenolysis, likely contributing to the observed increase in&#xD;
      EGP.&#xD;
&#xD;
      So far the likely interrelation between acute changes in hepatic glucose metabolism and&#xD;
      energy turnover contributing to increased hepatic glucose production induced by SGLT2&#xD;
      inhibition has not been studied. It is known that out of the 80% of oxygen consumption&#xD;
      coupled to ATP synthesis, 7- 10% is used by GNG. However, so far the effects of dapagliflozin&#xD;
      on acute changes in gluconeogenesis (GNG) and ATP turnover in hepatic tissue and on the time&#xD;
      course of hormones involved in hypoglycaemia counter regulation have not been studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in endogenous glucose production</measure>
    <time_frame>420 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic gluconeogenesis</measure>
    <time_frame>420 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic lipid content</measure>
    <time_frame>420 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic glycogen content</measure>
    <time_frame>420 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hepatic ATP concentrations</measure>
    <time_frame>420 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hormones involved in hypoglycemia counter regulation</measure>
    <time_frame>420 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolically Healthy Controls</condition>
  <arm_group>
    <arm_group_label>patients dapa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be administered Dapagliflozin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be administered a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls dapa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>controls will be administered Dapagliflozin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>controls will be administered a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>controls dapa</arm_group_label>
    <arm_group_label>patients dapa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>controls placebo</arm_group_label>
    <arm_group_label>patients placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for diabetic patients:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  BMI 23 - 35 kg/m2&#xD;
&#xD;
          -  Age between 18 - 75 years&#xD;
&#xD;
          -  HbA1c &lt; 7.5% while on dietary treatment only or&#xD;
             treatment!with!up!to!two!oral!antidiabetic!&#xD;
             agents!including!metformin,!alphaAglucosidase!inhibitor,!sulfonyl!urea!or!DPPAIV!inhib&#xD;
             itor.&#xD;
&#xD;
          -  Must have given written informed consent and be able to comply with all study&#xD;
             requirements&#xD;
&#xD;
          -  Males or females. Aged 18 to 75 years, inclusive, at the time of informed consent&#xD;
&#xD;
          -  Females: Non-pregnant and non-lactating; surgically sterile (e.g., tubal occlusion,&#xD;
             hysterectomy, bilateral salpingectomy, bilateral oophorectomy), post-menopausal&#xD;
             (defined as 12 months of spontaneous amenorrhea in females &gt; 55 years of age or, in&#xD;
             females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical&#xD;
             cause and FSH levels in the postmenopausal range for the laboratory involved),&#xD;
             abstinent, or if engaged in sexual relations of child-bearing potential, subject is&#xD;
             using an acceptable contraceptive method.&#xD;
&#xD;
          -  Body Mass Index (BMI) 23 - 35 kg/m2&#xD;
&#xD;
          -  Agree to maintain current diet and exercise regimen. Agree to abstain from alcoholic&#xD;
             beverages for at least 48 hours prior to clinic visits and not increase alcohol&#xD;
             consumption during the study&#xD;
&#xD;
        Exclusion criteria for diabetic patients:&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  treatment with more than 2 oral antidiabetic agents or treatment with insulin / SGLT2&#xD;
             inhibitor&#xD;
&#xD;
          -  regular medication&#xD;
&#xD;
          -  tendency towards claustrophobia&#xD;
&#xD;
          -  metal devices or other magnetic material in or on the subjects body which will be&#xD;
             hazardous for NMR investigation [heart pacemaker, brain (aneurysm) clip, nerve&#xD;
             stimulators, electrodes, ear implants, post coronary by-pass graft (epicardial pace&#xD;
             wires), penile implants, colored contact lenses, patch to deliver medications through&#xD;
             the skin, coiled spring intrauterine device, vascular filter for blood clots,&#xD;
             orthodontic braces, shunt-spinal or ventricular, any metal implants (rods, joints,&#xD;
             plates, pins, screws, nails, or clips), embolization coil, or any metal fragments or&#xD;
             shrapnel in the body].&#xD;
&#xD;
          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as&#xD;
             aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or alanine&#xD;
             aminotransferase (ALT) &gt;3x ULN, Total bilirubin &gt;2.0 mg/dL (34.2 μmol/L), positive&#xD;
             serologic evidence of current infectious liver disease including Hepatitis B viral&#xD;
             antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody&#xD;
&#xD;
          -  Creatinine Clearance: &lt;60 mL/min (calculated by Cockcroft-Gault formula) or a measured&#xD;
             serum creatinine value of &gt;1.5 mg/dL (133 μmol/L) for male patients and &gt;1.4 mg/dL&#xD;
             (124 μmol/L) for female patients, History of unstable or rapidly progressing renal&#xD;
             disease&#xD;
&#xD;
          -  History of diabetic ketoacidosis (DKA) requiring medical intervention (eg, emergency&#xD;
             room visit and/or hospitalization) within 1 month prior to the Screening visit.&#xD;
&#xD;
          -  Volume depleted patients.&#xD;
&#xD;
          -  Recent Cardiovascular Events in a patient:&#xD;
&#xD;
               -  Acute Coronary Syndrome (ACS) within 2 months prior to enrolment&#xD;
&#xD;
               -  Hospitalization for unstable angina or acute myocardial infarction within 2&#xD;
                  months prior to enrolment&#xD;
&#xD;
               -  Acute Stroke or TIA within two months prior to enrolment&#xD;
&#xD;
               -  Less than two months post coronary artery revascularization&#xD;
&#xD;
          -  Congestive heart failure defined as New York Heart Association (NYHA) class IV,&#xD;
             unstable or acute congestive heart failure.&#xD;
&#xD;
          -  Treatment with insulin, thiazolidinedione (e.g., pioglitazone), GLP-1 agonist, SGLT2&#xD;
             and other drugs that may affect plasma glucose level (including systemic&#xD;
             glucocorticoids) within 3 months prior to screening&#xD;
&#xD;
        Exclusion criteria for healthy controls:&#xD;
&#xD;
          -  Clinically!significant!abnormalities!in!medical!history!or!physical!examination +&#xD;
             smoking&#xD;
&#xD;
          -  regular medication&#xD;
&#xD;
          -  pregnancy, breast feeding&#xD;
&#xD;
          -  tendency towards claustrophobia&#xD;
&#xD;
          -  metal devices or other magnetic material in or on the subjects body which will be&#xD;
             hazardous for NMR investigation [heart pacemaker, brain (aneurysm) clip, nerve&#xD;
             stimulators, electrodes, ear implants, post coronary by-pass graft (epicardial pace&#xD;
             wires), penile implants, colored contact lenses, patch to deliver medications through&#xD;
             the skin, coiled spring intrauterine device, vascular filter for blood clots,&#xD;
             orthodontic braces, shunt-spinal or ventricular, any metal implants (rods, joints,&#xD;
             plates, pins, screws, nails, or clips), embolization coil, or any metal fragments or&#xD;
             shrapnel in the body].&#xD;
&#xD;
          -  Hepatic insufficiency and/or significant abnormal liver function defined as aspartate&#xD;
             aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or alanine aminotransferase&#xD;
             (ALT) &gt;3x ULN, Total bilirubin &gt;2.0 mg/dL (34.2 μmol/L), positive serologic evidence&#xD;
             of current infectious liver disease including Hepatitis B viral antibody IGM,&#xD;
             Hepatitis B surface antigen and Hepatitis C virus antibody&#xD;
&#xD;
          -  Creatinine Clearance: &lt;60 mL/min (calculated by Cockcroft-Gault formula) or a measured&#xD;
             serum creatinine value of &gt;1.5 mg/dL (133 μmol/L) for male patients and &gt;1.4 mg/dL&#xD;
             (124 μmol/L) for female patients, History of unstable or rapidly progressing renal&#xD;
             disease&#xD;
&#xD;
          -  Volume depleted patients. Patients at risk for volume depletion due to co-existing&#xD;
             conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Krebs, Prof. MD</last_name>
    <phone>0140400/431000</phone>
    <email>michael.krebs@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Of Vienna, Department of Internal Medicine III</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wolf, MD</last_name>
      <phone>004314040043110</phone>
      <email>peter.wolf@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Michael Krebs</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

